Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate–severe psoriasis

Giannetti, Alberto; Coppini, Maurizio; Bertazzoni, Maria Grazia; Califano, A; Altieri, Ermete; Pazzaglia, A; Lega, Mario; Lombardo, M.; Pelfini, C.; Fornasa, C. Veller; Rabbiosi, G.; Cespa, M.

doi:10.1016/s0926-9959(99)00056-2

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among an initial selection of 1348 references, we finally included 44 references, reporting data from 37 RCTs and eight cohort studies in the systematic review 6–49 . The detailed flowchart describing both selection process and reasons for exclusion is illustrated in Fig.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review

Sbidian

Maza

Montaudié³

et al. 2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review

Sbidian

Maza

Montaudié³

et al. 2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The speed of its action on psoriatic lesions is rather slow, but the lack of side‐effects such as skin atrophy and induction of telangiectasia favors its long‐term use. Topical vitamin D3 treatment is used as monotherapy, as combination therapy with topical corticosteroids, or with narrowband ultraviolet B therapy, cyclosporin, etretinate or methotrexate …”

Section: Discussionmentioning

confidence: 99%

Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab

Karakawa

Komine

Kishimoto

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Adalimumab is a biologic that is very effective for treatment of psoriasis. However, recalcitrant or recurrent lesions sometimes occur during treatment. Maxacalcitol is an active vitamin D3 ointment that is effective in treatment of psoriasis. Topical therapy may be beneficial in treatment of recalcitrant or recurrent lesions during treatment with systemic therapy, but there is little evidence on this topic. We investigated the effect of maxacalcitol on skin lesions during treatment with adalimumab in patients with psoriasis. Twelve patients with psoriasis were randomly assigned to two groups after informed consent - treatment with adalimumab only (n = 6), and treatment with adalimumab and maxacalcitol (n = 6) - and they were evaluated every 4 weeks for 44 weeks. Exacerbation was defined as an increase of the Psoriasis Area and Severity Index (PASI) score. The interval between adalimumab treatments was elongated to 3-4 weeks from 2 weeks according to the individual patient's condition. The PASI score was evaluated every 4 weeks, and the frequency of exacerbations was counted. The overall improvement in PASI score was not statistically different between the two groups, but the frequency of exacerbations was significantly less in the maxacalcitol combination group compared with the adalimumab monotherapy group (Mann-Whitney U-test, P < 0.05). The better control of skin lesions in patients who elongated the interval of adalimumab administration was achieved in the maxacalcitol combination group compared with the adalimumab monotherapy group. Topical maxacalcitol treatment is effective and useful in controlling skin lesions in patients with psoriasis when used in combination with adalimumab.

show abstract

“…The use of etretinate and phototherapy appear to be considerably safer and more practical compared with these treatments. However etretinate treatment can sometimes cause hepatic dysfunction or hyperlipidemia, and phototherapy requires frequent hospital visits. Therefore, the ideal treatment for the elderly patients with moderate to severe psoriasis and impaired QOL should have a higher efficacy without an increase in the risk of adverse events, together with a reduction in frequency of hospital visits.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis

Hayashi

Umezawa

Fukuchi

et al. 2014

The Journal of Dermatology

View full text Add to dashboard Cite

The ratio of the elderly among psoriasis patients has been increasing. However, satisfactory long-term management of psoriasis for the elderly is challenging because of the more frequent presence of comorbidities, and the higher risk of adverse events from systemic therapeutic agents than younger patients. The use of ustekinumab (UST) appears to be an appropriate systemic treatment because it is considered less likely to cause adverse events than other systemic treatments, as well as necessitating fewer hospital visits. Our retrospective study aimed to evaluate the efficacy and safety profile of UST in elderly patients with psoriasis. The study included 24 patients aged over 65 years (range, 65-88 years; mean, 73.1 years) with moderate to severe plaque psoriasis with impaired quality of life. Efficacy and safety were assessed over a 1-year period using the Psoriasis Area and Severity Index (PASI) and the Dermatology Live Quality Index (DLQI). The efficacy was evaluated by the proportion of subjects who achieved ≥75% reduction in PASI score (PASI 75). PASI 75 responses were 56.5% at week 16, 59.1% at week 28, and 60.0% at week 52. None of the patients developed any serious infection during the 1-year treatment. The mean DLQI score at weeks 0, 16, 28, and 52 was 7.8 ± 6.0, 2.5 ± 3.4, 1.4 ± 1.7, and 1.2 ± 1.7, respectively. UST showed sufficient efficacy for elderly patients with psoriasis without any serious infection over the 1-year treatment. Our results suggest that UST is the preferable agent for the treatment of elderly patients with psoriasis.

show abstract

Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate–severe psoriasis

Abstract: These findings suggest that patients with moderate-severe psoriasis might benefit from treatment with etretinate plus calcipotriol, with the aim of achieving a faster response and an overall smaller total dose of etretinate.

Cited by 5 publications

References 6 publications

Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review

Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review

Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab

Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis

Contact Info

Product

Resources

About